Objectives: Antimicrobial therapy for sepsis caused by carbapenem-and colistin-resistant Klebsiella pneumoniae is not well established. We hypothesized that the early use of gentamicin in cases due to susceptible organisms would decrease the crude mortality rate of this infection.
Introduction
Infections caused by carbapenemase-producing Klebsiella pneumoniae isolates (KPC-Kp) are an emerging problem worldwide. 1 Due to its high spreading capacity, outbreaks are increasingly frequent in hospitals, and this microorganism is now considered endemic in several countries. 2 The reported crude mortality rate of invasive infections due to KPC-Kp is very high (39% -69%) 3 -9 and frequently higher than that of K. pneumoniae strains that do not produce these enzymes. 5, 10, 11 A significant problem in managing KPC-Kp infections is to find the appropriate antibiotic regimen as carbapenem resistance is often accompanied by resistance to other families of first-line antibiotics, such as cephalosporins, b-lactamase inhibitors or quinolones. 12, 13 This makes it necessary to use second-line antibiotics such as tigecycline, aminoglycosides, colistin or fosfomycin. 14, 15 Some studies have reported an association between lower mortality and the use of carbapenems in combination with other active agents, particularly when the strains have shown low levels of in vitro resistance to those antimicrobials. 6, 8 However, some case series have reported good results with regimens that do not include carbapenems 16 or active aminoglycosides. 14, 15, 17 However, the best therapeutic regimen for the treatment of KPC-Kp infections and the specific effectiveness of aminoglycosides in these cases is not well defined. The aim of this study was to analyse the impact of gentamicin therapy on mortality from sepsis caused by KPC-Kp during an outbreak due to a highly resistant clone.
Methods

Study design
An observational, retrospective cohort study was conducted in a 950 bed teaching hospital with an active transplant programme. From 1 June 2012 to 15 February 2013 all KPC-Kp isolates were collected from the database of the Microbiology Service of the Hospital Universitario Reina Sofia-IMIBIC in the context of an infectious outbreak caused by this microorganism. The clinical records of patients with KPC-Kp isolates were reviewed. All cases that met the following criteria were included in the study: (i) clinical evidence of infection with criteria for sepsis, severe sepsis or septic shock (see the definitions below); and (ii) the administration of antibiotic therapy (empirical and/or targeted) for at least 48 h with ≥1 active antibiotic in vitro (including cases of intermediate susceptibility). Meropenem was considered active in XDR and pandrug-resistant (PDR) isolates, following the results of Tumbarello et al. 8 Only those cases in which empirical treatment was initiated within 12 h after the onset of symptoms and cases in which targeted treatment was initiated within 5 days after obtaining cultures were included. Recurrent infections were excluded.
Variables
The main outcome variable of the study was crude mortality within 30 days of KPC-Kp isolation. The explanatory variables were gender, age, disease severity using the Charlson Comorbidity Index, 18 hospitalization in the previous 3 months, admission to ICU, invasive procedures in the week prior to the diagnosis of infection (a need for mechanical ventilation, use of a central venous catheter or a urinary catheter), renal function on the day of diagnosis of the infection, site of infection, severity of presentation (sepsis, severe sepsis or septic shock), presence of bacteraemia, and empirical and targeted antibiotic treatment. Data were collected from clinical records using a specific questionnaire.
Definitions
The definitions were established prior to data collection and analysis. The criteria proposed by the Centres for Disease Control and Prevention 19 and interpreted by clinical experts were used to establish the diagnostic criteria for infection and infection types. Sepsis was defined as the presence of both infection and a systemic inflammatory response according to the criteria of the International Sepsis Definitions Conference. 20 Severe sepsis was defined as sepsis complicated by organ dysfunction with reversible hypotension after volume infusion. 20 Septic shock was defined as sepsis with organ dysfunction and persistent hypotension despite volume infusion. 20 The day of onset of infection was defined as the day the index culture was collected and the microorganism was isolated. The Cockroft -Gault formula 21 was used to calculate CL CR . Renal failure was defined as CL CR , 60 mL/min.
An antibiotic regimen was considered 'active' when it included at least one antibiotic to which the strain was susceptible or exhibited intermediate susceptibility in vitro according to EUCAST breakpoints. Treatment regimens including at least one drug to which the isolate was fully susceptible according to EUCAST breakpoints were considered 'optimal'. Treatments with gentamicin were considered optimal when the isolate had an MIC ≤4 mg/L. Treatment regimens in which no fully active drug was included but included at least one drug with intermediate activity (or resistance in the case of meropenem) were considered 'suboptimal'. The time to the initiation of optimal treatment was also recorded. Regardless of the in vitro activity of the drugs, treatment regimens were classified as monotherapy (single drug) or combination therapy (antibiotics active only against Gram-positive organisms, such as glycopeptides, daptomycin or linezolid, and those active against anaerobes, such as metronidazole, were not considered). Given that antibiotic therapies in these patients often vary, thus making it difficult to assign them to a specific regimen, patients were assigned to a regimen only if it was initiated during the first 5 days after diagnosis and maintained for at least 5 days (or at least 48 h if the patient died within 5 days of treatment). Patients who died before receiving 48 h of treatment with any antibiotic regimen were excluded from the analysis.
The study was approved by the Ethics Committee of the Hospital Universitario Reina Sofía, which waived the need to obtain written informed consent. All data collected were anonymized.
Microbiological variables and antibiotic susceptibility studies
Selected K. pneumoniae isolates from the outbreak had previously been characterized as producing KPC-3. 22 Briefly, susceptibility to antimicrobials was studied by microdilution, which showed that the isolates were resistant to penicillins, cephalosporins, aztreonam, fluoroquinolones, amikacin, tobramycin, co-trimoxazole, chloramphenicol, ertapenem, imipenem and meropenem (.32 mg/L). Some isolates were susceptible to tigecycline, fosfomycin and gentamicin according to the EUCAST breakpoints. Carbapenemase genes were identified by PCR methods using specific primers for groups A, B and D and further sequencing. Other bla genes were also detected by PCR methods. All isolates harboured bla KPC-3 , bla SHV-11 and bla TEM-1 genes. All isolates showed 99.5% similarity and were assigned to clone ST512 by MLST.
Additional isolates included in this study were considered to belong to the epidemic clone if they showed the resistance pattern described above. For these isolates, identification and susceptibility testing was performed by MicroScan (Dade MicroScan, Sacramento, CA, USA). MICs were classified according to EUCAST breakpoints.
MDR, XDR and PDR K. pneumoniae were defined according to a recent consensus document. 23 
Statistical analysis
Patients who died within the first 30 days were compared with survivors in terms of exposure to the studied variables. The results are expressed as mean+SD, median (range) (quantitative variables) or percentages of the group to which they belonged (qualitative variables). Differences between patients treated with and without gentamicin were analysed by univariate logistic regression. The OR was calculated with 95% CI. Survival curves were constructed using the Kaplan -Meier method and were compared using the log-rank test. To identify risk factors for mortality, univariate and multivariate analysis was performed using Cox regression and calculation of HRs with 95% CIs. For the multivariate analysis, the hypothesis that the use of gentamicin was associated with reduced mortality was considered. The limited number of patients did not allow us to develop a single, comprehensive multivariate model that included all potential variables influencing mortality because it would have been oversaturated. Alternatively, we developed different multivariate models using a forward stepwise strategy, in which the association between our variable of interest (therapy with gentamicin) and mortality was adjusted by triples or pairs of potential confounders.
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Results
Clinical characteristics of the patients
During the study period, KPC-Kp were isolated from 78 patients, of whom 67 had active infection and 50 met the criteria for sepsis as well as the other criteria for inclusion in this study. The 30 day crude mortality rate following the diagnosis of infection was 38% (19/50 patients).
The overall characteristics of the cohort and subgroups who died and survived are shown in Table 1 . Most patients had underlying diseases, had undergone invasive procedures, and had been admitted to ICUs or medical services. The most common types of infection were pneumonia and urinary tract infections, and around one-third of patients had bacteraemia. Four patients were suffering from purulent tracheobronchitis associated with mechanical ventilation.
Microbiological characteristics
Tigecycline and fosfomycin were active against 36 (72.0%) and 10 (20.0%) isolates, respectively. With regard to gentamicin, 18 isolates (36.0%) were susceptible (MIC ≤2 mg/L), 31 (62.0%) showed intermediate susceptibility (MIC .2 to ≤4 mg/L) and 1 (2.0%) was resistant (MIC .4 mg/L). All isolates showed resistance to other antibiotics including colistin and meropenem (MIC .32 mg/L for all isolates). The strains isolated from the patients were classified as MDR for 5 patients (10.0%), XDR for 35 patients (70.0%) and PDR for 10 patients (20.0%). All 10 patients with PDR isolates were included in the suboptimal treatment group.
Antibiotic treatment
All patients received empirical antibiotic treatment, but optimal empirical treatments were used in only six patients (12%). Targeted treatment was optimal in 37 patients (74%). Tables 1  and 2 show the antibiotic regimens used.
Only one patient was infected with a gentamicin-resistant KPC-Kp strain. However, this antibiotic was targeted in only 29 patients (58%). The dose administered was 4 -5 mg/kg/24 h and corrected following the monitoring of blood levels to obtain a pharmacokinetic goal of a C max of 15 -20 mg/L and a C min of ≤1 mg/L. The antibiotic was administered as monotherapy in 8 patients (4 urinary tract infections, 1 pneumonia, 1 purulent tracheobronchitis, 1 non-catheter-related bacteraemia, and 1 surgical wound infection) and in combination with another drug in 21 patients. Gentamicin was initiated 3.5+1.0 days after diagnosis. Gentamicin was not used in 21 patients (42%), one of whom was the patient with a resistant strain. The remaining 20 patients had susceptible or intermediate strains. Patients who did not receive gentamicin received treatment for 7.1+4.5 days (range 2 -14 days). Tables 3 and 4 show the main characteristics of the patients who received gentamicin. In patients who received gentamicin, renal failure (17.2% versus 52.4%), hospitalization in the previous 3 months (17.2% versus 52.4%) and use of cephalosporins in the previous month (6.9% versus 47.6%) were less frequent than among patients who did not receive gentamicin. The concomitant use of targeted tigecycline was more frequent in these patients (72.4% versus 38.1%).
A loading dose of tigecycline was administered followed by 100 mg/12 h (200 mg loading dose) in 12 cases: 7 cases of nosocomial pneumonia (38.9% of the 18 cases treated with tigecycline), 2 cases of bacteraemia, 2 surgical wound infections, and 1 infection of the CNS. A conventional dose of 50 mg/12 h (100 mg loading dose) was administered in the remaining cases. Meropenem was administered as an extended infusion (≥3 h) at a dose of 1 -2 g every 6 -8 h.
Risk factors for 30 day crude mortality
Univariate analysis showed differences between patients who died and those who survived ( Table 1 ). The group who died were older (median 67 versus 55 years of age) and the most frequent underlying disease was cancer (42.1% versus 9.7%). Renal failure (52.6% versus 19.4%), hospitalization in the previous 3 months (52.6% versus 19.4%), use of quinolones in the previous month (63.2% versus 29.0%) and severe sepsis/septic shock (94.7% versus 40.0%) were more frequent. Optimal targeted treatment (47.4% versus 90.3%) and use of gentamicin (31.6% versus 74.2%) were less frequent. The use of targeted meropenem was associated with higher mortality (Table 1) .
The use of targeted treatment with gentamicin was associated with lower mortality compared with the use of targeted treatment without gentamicin (optimal or suboptimal) (20.7% versus 61.9%, P ¼ 0.02) ( Table 4 ). Mortality was significantly reduced when the strain was susceptible to gentamicin (7.7% versus 80.0%, P¼ 0.008) and lower when the strain showed intermediate Gonzalez-Padilla et al.
susceptibility (31.2% versus 53.3%, P ¼ 0.133). In patients treated with gentamicin, mortality was lower if the strain was susceptible (MIC ≤ 2) rather than had intermediate susceptibility (7.7% versus 31.2%, P ¼0.183). Mortality in the group of patients with optimal targeted treatment containing gentamicin was 20.7%, compared with 37.5% of patients with optimal targeted treatment without gentamicin (P ¼ 0.21).
The survival analysis performed using Kaplan -Meier curves showed that patients treated with gentamicin had higher survival rates at 30 days after diagnosis (Figure 1 , log-rank test 11.9, P ¼ 0.001). Figure 2 shows the different impact on mortality of suboptimal targeted treatment and optimal targeted treatment with or without gentamicin (log-rank test 17.3, P,0.001). Table 5 shows the eight models obtained from the multivariate analysis to test the study hypothesis. In all the models, the use of gentamicin was found to provide protection against mortality independently of other potential confounding variables, such as any optimal targeted treatment (model 1), optimal empirical treatment (model 2), having severe sepsis/septic shock (models 1 and 3), age (models 1 and 4), urinary tract infection (model 5), CL CR (models 2 -8), neoplasia as underlying disease (model 6), treatment with tigecycline in the first week (model 7), and hospitalization in the previous 3 months (model 8).
Discussion
The mortality of the patients included in our study (38%) confirms the high mortality of infections caused by carbapenemaseproducing K. pneumoniae, particularly KPC-Kp (39% -69%). However, studies published to date do not yield uniform results. The wide variability observed in mortality rates, which were generally higher than in our study, is probably due to differences in the characteristics of the patients studied (age, comorbidities, severity and types of infection), the specific type of carbapenemase and the resistance profile of the isolates. 3 -10,24 -26 Nonetheless, it is essential to determine the most effective therapies in treating these infections, with a view to reducing mortality.
Due to the lack of prospective randomized studies with new or existing active antibiotics, it is necessary to perform observational analyses of the therapeutic strategies used in clinical practice. Most studies on the treatment of KPC-Kp have been performed in patients with bacteraemia 6 -9 and lack information on other types of infections that are underrepresented in those studies, or have included patients with sepsis but without bacteraemia. Our study included patients with various infections, but with sepsis criteria in all cases. In addition, other studies have often included strains with relatively low MICs of carbapenems and/or susceptibility to colistin, 6 -8,16 while our study provides information about highly carbapenem-resistant and colistinresistant strains that are susceptible to gentamicin. Moreover, criteria for assigning patients to specific antibiotic regimens were not clearly specified in some studies, which is key in these infections in which regimens are frequently changed during the course of the disease.
In our study, only 12% of patients received optimal empirical therapy, which may have contributed to the high mortality rate. Use of optimal targeted high-dose tigecycline, n (%) 7 (24. Monotherapy versus combination therapy refers to active antibiotics. All patients classified as receiving optimal monotherapy with gentamicin received other non-active antibiotics. c Not applicable. One of the frequencies was 100% or 0%.
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There may be a tendency to delay the administration of potentially active drugs due to a lack of experience in using them or to avoid adverse effects, thus underestimating their usefulness.
It is important to emphasize that the best therapeutic options should be indicated early on based on the knowledge of the resistance profile of each outbreak. The results of our study confirm that mortality is directly related to the use of active drugs. The results of several retrospective studies suggest that combination therapy is better than monotherapy to treat serious infections caused by KPC-Kp. 6 -8,14,15,27 Nonetheless, there is little agreement over the best combination of antibiotics or the importance of the number of active drugs in vitro or the family of these drugs depending on the susceptibility of the strain. In the univariate analysis of our study, combination therapy was associated with lower mortality, although the differences were not statistically significant ( Table 1 ). The effectiveness of each regimen may depend on the activity of the antibiotics used. It is therefore essential not only to establish the efficacy of combination therapy, but to determine which first-line drugs should be used in these combinations.
The use of targeted gentamicin in the conditions evaluated in our study was associated with a 41.2% reduction in crude mortality at 30 days. This could be related to the fact that the use of optimal targeted treatment was more frequent among patients treated with gentamicin. Nevertheless, in the multivariate models we obtained, this beneficial effect on mortality was maintained by adjusting the results for optimal targeted therapy, as well as other potential confounding variables such as renal function, age, severity of infection, site of infection, combined treatment with tigecycline or previous hospitalization. The fact that the adjusted HR was very similar in all the models reinforces the association. It is important to highlight that, contrary to what might initially be thought, the beneficial effect of gentamicin cannot be explained because it has been used in patients with less severe and more easily treatable infections (such as urinary tract infections) or with better renal function, given that all these factors were considered in the models analysed. We believe that the effect of gentamicin indicates the clinical activity of this drug. Several authors have reported good results when using aminoglycosides in cases of KPC-Kp infection susceptible to this group of antibiotics, especially urinary tract infections. 14, 15, 17 Unfortunately, the sample size does not allow us to obtain more specific findings in subgroups of patients.
The applicability of our results is obvious when the carbapenemand colistin-resistant K. pneumoniae strain is susceptible to gentamicin. Nevertheless, it is important to determine whether gentamicin should be maintained in the combined therapeutic regimen when the strain shows intermediate susceptibility. Meropenem is considered effective in KPC-Kp infections when the MIC is ≤8 mg/L. 6, 8, 27, 28 One study has shown meropenem to be clinically effective even when the strains had an MIC of ≥16 mg/L. 6 In our study, the use of targeted meropenem was associated with higher mortality. Our results may be explained by the high meropenem MICs of our isolates (.32 mg/L) and by the fact that no patients were administered the maximum doses. In this situation, it is impossible to achieve adequate pharmacodynamic targets, even when using an extended infusion. 28, 29 In addition, meropenem was frequently used in monotherapy and in PDR isolates. Our results therefore suggest that when meropenem is used (in the absence of other valid options or with severe urinary tract infection), it should be combined with gentamicin.
In conclusion, the results of this study indicate that gentamicin use in patients with sepsis caused by carbapenem/colistinresistant K. pneumoniae is associated with improved survival. Nonetheless, the study has some limitations that could affect this conclusion: (i) there were significant demographic and clinical differences between survivors and those who died; (ii) the study included various types of infection, which are difficult to compare; (iii) although all patients had sepsis, only a small number had bacteraemia; (iv) the majority of patients had lower respiratory tract infections, which are less responsive to gentamicin treatment, something that should be considered in the context of isolates showing resistance to all first-line drugs for the treatment of pneumonia; (v) two-thirds of patients had strains with intermediate susceptibility to gentamicin; and (vi) active targeted treatment was initiated in 3 -5 days after the onset of sepsis in some patients, reflecting the delay in susceptibility test reporting that frequently occurs with XDR and PDR organisms; however, the potential deleterious effect of this delay may have been compensated by the fact that this also selected survivors.
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